Leading Gastroenterologist Answers Questions on Key Controversial Topics in Inflammatory Bowel Diseases During Crohn's & Colitis Foundation Interactive Teleconference/Webcast
Registration Open for May 7 Event
WHO: Collectively known as inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis are chronic digestive diseases affecting over 1.4 million Americans. Due to the complexity of, and stigma attached to these diseases that inflame the digestive tract, a great deal of awareness and insight into the diseases is lacking. As very personal diseases often causing persistent diarrhea, fever, and weight loss, patients often don't feel comfortable talking about life with IBD with others, and seek answers to disease-specific questions from trusted sources such as the Crohn's & Colitis Foundation. Whether a patient is newly diagnosed, has lived with Crohn's or colitis for years, or has a loved one who suffers from IBD, it is important to understand the impact of these diseases on day-to-day life.
WHAT: The Crohn's & Colitis Foundation is hosting an interactive educational teleconference/webcast, supported by an educational grant by Procter & Gamble. Interview with an Expert: Answers to Key Questions in Inflammatory Bowel Diseases has been developed to meet the needs of patients seeking answers to questions on key controversial topics.
Nationally-recognized expert, Stephen Hanauer, MD, Crohn's & Colitis Foundation of America National Scientific Advisory Committee Member and Professor of Medicine and Clinical Pharmacology, University of Chicago Pritzker School of Medicine and Chief of Gastroenterology, Hepatology and Nutrition, University of Chicago Medical Center, will speak on this live event and take questions from listeners.
WHY: The Crohn's & Colitis Foundation has defined the field of research into these intractable digestive diseases for nearly a half-century, playing a role in every major scientific breakthrough in IBD, from generating data that led to new therapies to the discovery of the first gene for Crohn's. Dr. Hanauer will provide participants with solid answers to key controversial questions about IBD, resulting from his experience and CCFA's solid research findings, including:
• What role does stress play in IBD? • What are the long-term side effects of IBD medications? • What is the impact of smoking on IBD symptoms?
WHEN: Thursday, May 7, at
WHERE: Dial-in from any phone to hear the presentation and participate in an interactive question-and-answer session, or log on to any computer to hear the presentation, see the program slides and submit questions.
Registration is available at no cost to participants via an online portal at www.ccfa.org/webcasts/keyquestions and by phone at 877-547-5641, ext. 310.
About Crohn's Disease & Ulcerative Colitis Crohn's disease and ulcerative colitis are painful, medically incurable illnesses that attack the digestive system. Crohn's disease may attack anywhere from the mouth to the anus, while ulcerative colitis inflames only the large intestine (colon). Symptoms may include abdominal pain, persistent diarrhea, rectal bleeding, fever and weight loss. Many patients require hospitalization and surgery. These illnesses can cause severe complications, including colon cancer in patients with long-term disease. Some 1.4 million American adults and children suffer from Crohn's disease or ulcerative colitis, with as many as 150,000 under the age of 18. Most people develop the diseases between the ages of 15 and 35.
About the Crohn's & Colitis Foundation The Crohn's & Colitis Foundation of America's mission is to cure Crohn's disease and ulcerative colitis, and to improve the quality of life of children and adults affected by these diseases. The Foundation ranks third among leading health non-profits in the percentage of expense devoted to research toward a cure, with more than 81 cents of every dollar the Foundation spends goes to mission-critical programs. The Foundation consistently meets the standards of organizations that monitor charities, including the Better Business Bureau's Wise Giving Alliance (give.org) and the American Institute of Philanthropy (charitywatch.org). For more information, contact the Foundation at 800-932-2423 or visit www.ccfa.org.
About Procter & Gamble (NYSE:PG) Three billion times a day, P&G brands touch the lives of people around the world. The company has one of the strongest portfolios of trusted, quality, leadership brands, including Actonel® (risedronate sodium) tablets, Enablex® (darifenacin) extended-release tablets, Prilosec OTC®, Metamucil®, Fibersure®, Align®, Pepto-Bismol®, Vicks®, PUR®, Crest® and Oral-B®. The P&G community consists of more than 135,000 employees working in more than 80 countries worldwide. For more information on P&GP and its prescription product portfolio, please visit www.pgpharma.com.
###
MEDIA CONTACT: Ariella Levine Crohn's & Colitis Foundation 646-943-7430 alevine@ccfa.org
